Among 14 nonbariatric weight-loss patients using pooled GLP-1 analogs including liraglutide who underwent synchronous full abdominoplasty and mastopexy, no complications occurred.
In plain wordsAmong 14 people using pooled GLP-1 analogs including liraglutide who had abdominoplasty and mastopexy, no complications occurred.
- Peptide
- Liraglutide
- Outcome
- Not applicableSurgical complications
- Study
n = 14
- Outcome group
- Adverse events · Whole body
Measurements
- Patients using GLP-1 receptor agonists
- 14
- liraglutide or tirzepatide
Source sentences
Notably, no complications occurred in patients who lost weight with GLP-1 analogs.
3 context sentences(design, population, supporting numbers)
Forty-nine patients had undergone bariatric surgery, whereas 52 achieved weight loss without bariatric surgery, including 14 patients using GLP-1 receptor agonists (liraglutide or tirzepatide).
Between January 2015 and August 2025, 101 consecutive weight-loss patients undergoing synchronous full abdominoplasty and mastopexy with a superomedial pedicle were prospectively enrolled.
Demographic characteristics, weight loss parameters, serum albumin levels, operative details, and complications (classified by Clavien-Dindo) were recorded.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.